利妥昔单抗联合化疗及造血干细胞移植治疗难治性弥漫大B细胞淋巴瘤临床观察  

A ease report of successful treatment of rituximab combined chemotherapy and hematopoietie stem cell transplantation for refractory diffuse large B cell lymphoma and literature review

作　　者：郭智[1] 何学鹏[1] 杨凯[1] 刘晓东[1] 王丙然[1] 刘丹[1] 陈惠仁[1] 

机构地区：[1]北京军区总医院血液病科,100700

出　　处：《中国医药》2011年第5期574-575,共2页China Medicine

摘　　要：目的探讨利妥昔单抗联合化疗及造血干细胞移植治疗难治性弥漫大B细胞淋巴瘤（DL-BCL）的临床疗效和安全性评价。方法回顾性分析1例应用利妥昔单抗联合化疗及造血干细胞移植治疗的难治性DLBCL患者的临床资料，并结合文献复习对此方法治疗难治性DLBCL的临床疗效和安全性进行评价。结果1例难治性DLBCL患者先后予各种方案化疗后未获得缓解，改为利妥昔单抗联合化疗及造血干细胞移植治疗后，造血重建顺利，取得完全缓解，相关并发症控制较好，随访至2010年11月1日一直长期无病生存。结论利妥昔单抗联合化疗及造血干细胞移植治疗难治性DLBCL是安全有效的治疗手段。Objective To report the clinical efficacy and safety of rituximab combined with autologans hem- atopoietlc stem cell transplantation in a case of refractory diffuse large B cell lymphoma. Methods Clinical data of a case in rituximab combined chemotherapy and hematopoietlc stem cell transplantation for refractory diffuse large B cell lymphoma was analyzed. The efficacy and safety for the program with literature review were evaluated. Results The patient did not achieve remission with various chemotherapy regimens. After using autologous hematopoietic stem cell transplantation with rituximab, the hematopoietic was rebuilded successfully, symptoms were complete re- lieved, complications were well controlled. Follow-up to November 1, 2010, the patient was disease-free survival. Conclusion Pdtuximab combined with autologous hematopoietic stem cell transplantation is a safe and effective treatment of refractory diffuse large B cell lymphoma.

关 键 词：淋巴瘤 大细胞 弥漫性 造血干细胞移植 利妥昔单抗 

分 类 号：R733[医药卫生—肿瘤]